HTRN's revenue for fourth-quarter 2009 totaled $50.3M: MicroStockProfit.com

May 7 2010

MicroStockProfit.com announces an investment report featuring HealthTronics Inc. (Nasdaq:HTRN). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/ads/HTRN

HealthTronics Inc. (HTRN) provides healthcare services and manufactures medical devices, primarily for the urology community. The Company provides lithotripsy services, which is a medical procedure where a device called a lithotripter transmits high-energy shockwaves through the body to break up kidney stones. Its lithotripsy services are provided principally through limited partnerships and other entities that it manages, which use lithotripters. During the year ended December 31, 2009, physicians who are affiliated with the Company used its lithotripters to perform approximately 50,000 procedures in the United States. HTRN has two types of contracts, retail and wholesale, that it enters into in providing its lithotripsy services. Retail contracts are agreements where it contracts with the hospital and private insurance payors. Wholesale contracts are agreements where it contracts only with the hospital. 

Message Board Search for HTRN: http://www.boardcentral.com/boards/HTRN

In the report, the analyst notes:

"Revenue from continuing operations for the fourth quarter of 2009 totaled $50.3 million, up from $44.6 million in the fourth quarter of 2008. The Company's net loss for the fourth quarter of 2009, in accordance with generally accepted accounting principles ("GAAP"), totaled $2.3 million or $0.05 per diluted share.  

"HTRN, a leading provider of urological products and services, recently announced that it has signed a definitive merger agreement with Endo Pharmaceuticals pursuant to which Endo will acquire HTRN. Under the terms of the merger agreement, Endo will commence an all cash tender offer to acquire all of the outstanding shares of HTRN common stock for approximately $223 million or $4.85 cash per HTRN share plus the assumption of debt. The transaction has been approved by the boards of directors of both companies."